


Quality Content • Resource Management • Access • Integration • Consultation



Página de Acesso:

http://academic.oup.com/journals



Resources for...









Journals A to Z

Journals by Subject ▼

Customer Services ▼

Resources ▼





Arts and humanities ←

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

A

Adaptation

African Affairs

The American Historical Review

American Journal of Legal History

American Literary History

Analysis

Applied Linguistics

Aristotelian Society Supplementary Volume

B

The British Journal of Aesthetics The British Journal for the Philosophy of Science

Connect

f Facebook ✓ Join our mailing list

Twitter

W Blog

▶ YouTube

Useful links

Changes to our list

Dispatch dates

Frequently asked questions

Latest Tweets





Increased Impact Factor

https://academic.oup.com/applij

Volume 37, Issue 6

December 2016

Anna Mauranen

Sign In ▼ Register

ACADEMIC

Journals A to Z

Journals by Subject ▼

Customer Services ▼

Resources ▼

Clicando em Sign in, terá acesso a essa página, que possui um link para o registro da sua senha personalizada.

Advanced Search


Register

Register for an Oxford Academic account to purchase searches.	content, get email alerts, and save
Already have an Oxford Academic account? Sign in	
* = Required Field	Preencha este formulário e clique em Register para ter acesso a recursos como salvar pesquisas,
Email Address*	criar alertas e muito mais.
Password*	
Confirm Password*	
Show Password	

Receive New issue email alert for Applied Linguistics

Register

By clicking Register, you agree to our privacy policy & legal notice.



Resources for...














About us Contact us

OUPblog Careers

Join our mailing list

Connect

Resources Authors

Librarians

Shop OUP Academic Oxford Dictionaries

Explore

Oxford University Press is a department of the University of Oxford. It furthers the University's objective of excellence in research, scholarship, and education

Journals **ACADEMIC** Journals by Subject ▼ Journals A to Z Activate Subscriptions and Trials

Customer Services ▼

Este recurso permite ao usuário salvar pesquisas de seu interesse.

Advanced Search

Saved searches Z

No Saved Searches.

Institutional Settings Edit Personal Details

Change Email Address

Short Term Access

Usage Statistics

Current Online Subscriptions /

Change Password

Email Alerts

Saved Searches

Communication Preferences

About us

Careers

Contact us

Connect Join our mailing list OUPblog

Authors Librarians

Resources

Explore

Shop OUP Academic

Oxford University Press is a department of the University of Oxford. It furthers the University's objective of excellence Oxford Dictionaries in research, scholarship, and education

Journals A to Z

Journals by Subject ▼

Customer Services ▼

Resources ▼







A trusted society partner

Oxford Academic publishes more than 200 journals on behalf of learned societies around the world.



Open access

We are mission-driven to facilitate the widest possible dissemination of high-quality research.



Altmetric scores

We use altmetrics to highlight a paper's impact within and beyond the academic sphere.


Resources for...











OXFORD Journals

Utilize as facetas abaixo para refinar os resultados da sua pesquisa

ubject ▼ Customer Services ▼ Resources ▼ Q Advanced Search

1 2 3 4 5 Next

Modify your search

headache AND "YOUNG W

Filter ▼

Add term Update

Format

Journal Articles (235)

Article Type

- Research Article (157)
- Review Article (34)
- Other (21)
- Abstract (8)
- Case Report (4)
- Letter (4)
- Brief Report (2)
- Editorial (2)
- News (2)
- Discussion (1)

1-20 of 235 results for

Sort by Relevance

headache AND "YOUNG WOMEN"

.

Save

Migraine and stroke in **young women**M.J. Cuadrado, M.A. Khamashta, G.R.V. Hughes

in QJM: An International Journal of Medicine

Published: 01 May 2000

... in the very resistant patient, anticoagulants may be an alternative therapy.

12 References 1 Chang CL, Donaghy M, Poulter N and World Health

Organisation Collaborative Study of Cardiovascular Disease and Steroid

Hormone Cont Clique para visualizar o

Abstract (resumo) do artigo

Extract v


Journal Articles

men: case-control

Association of inflammation markers with menstrual symptom severity and premenstrual syndrome in




Issues More Content ▼ Publish ▼ Purchase Alerts About ▼ Q Advanced Search



AN INTERNATIONAL JOURNAL OF MEDICINE





No cover image available

Volume 93, Issue 5

Article Contents

May 2000

References

< Previous Next >

cases of migraine followed by stroke not frequently mentioned in the literature—the presence of antiphospholipid antibodies (aPL). Following the description of the antiphospholipid syndrome (APS) in 1983,⁶ it has become clear that headaches, including migraine, and

strokes are major features of the disease. Our own clinical experience in the lupus unit at St Thomas Hospital points towards the juxtaposition of severe headache including migraine and the development of stroke in a number of young individuals, especially

We would like to suggest a possible pathogenetic link between some

patients with migraine and subsequent stroke. In every patients with migraine and subsequent stroke. In every patients migraine antedated the stroke (mean 29±21 months, range months). Magnetic Resonance Imaging (MRI) before stroke was normal in six patients, while two showed multiple high-intensity small images compatible with small-vessel disease (patients 7 and 8). All patients were receiving treatment for migraine as shown in Table 1. Interestingly, in two patients (patients 2 and 6), severe recurrent migraine attacks improved following the use of low-dose aspirin (75 mg/day). A further two patients (Visualize artigos que

with warfarin as therapeutic trial, show

of migraine. All patients received warfa

response to warfarin.

and those four who still suffered with rengrame.

The pathogenesis of migraine in APS is unknown. Possible mechanisms include the activation and aggregation of platelets, and the expression on endothelial cells of proteins such as endothelin-1, or tissue factor, the major initiator of the coagulation cascade *in vivo*. The mechanism behind the reduction in migrainous headaches during warfarin treatment in some of our

citaram o artigo principal

em outras bases

Email alerts

View Metrics

ai ticics

New issue alert

New advance articles alert

Article activity alert

Receive exclusive offers and updates from Oxford Academic

Citing articles via

Web of Science (18)

Google Scholar

CrossRef

Most Read Most Cited

patients is unclear, however, the dramatic response leads us to

Texto Completo no Formato PDF

J Antimicrob Chemother doi:10.1093/jac/dkw458 Journal of Antimicrobial Chemotherapy

Pharmacokinetics and tolerability of ABX464, a novel first-in-class compound to treat HIV infection, in healthy HIV-uninfected subjects

Didier Scherrer¹, Regine Rouzier², P. Noel Barrett³, Jean-Marc Steens¹, Paul Gineste^{1*}, Robert L. Murphy⁴,

Jamal Tazi⁵ and Hartmut J. Ehrlich¹

¹ABIVAX, 5 Rue de la Baume, 75008 Paris, France; ²Centre Cap Montpellier, 9 avenue Charles Flahault, 34094 Montpellier, France; ³Independent Consultant c/o ABIVAX, 5 Rue de la Baume, Paris, France; ⁴Northwestern University Feinberg School of Medicine, 645 N Michigan Avenue, Suite 1058, Chicago, IL 60611, USA; ⁵Institut de Génétique Moléculaire, University of Montpellier, 1919 Route de Mende, 34293 Montpellier, France

*Corresponding author. E-mail: paul.gineste@abivax.com

Received 9 June 2016; returned 5 August 2016; revised 16 September 2016; accepted 27 September 2016

Background: An anti-HIV compound (ABX464) has been developed with a novel mechanism of activity in that it blocks viral gene expression in cells that are already infected.

Objectives: A first-in-man study was conducted to determine the pharmacokinetic and safety profiles of ABX464. This was carried out as an open label, parallel group, single ascending dose, exploratory study.

Methods: Twenty-four male subjects in good health without HIV infection, aged from 18 to 55 years old, with BMIs of 18-27 kg/m² were included. A single oral dose of ABX464 (50, 100, 150 or 200 mg) was administered on the morning of day 0 after overnight fasting, with follow-up for 45 days. Safety assessments consisted of vital signs, electrocardiogram, physical examination, laboratory tests and urinalysis. Pharmacokinetic parameters were calculated for ABX464 and its main metabolite ABX-464-N-glucuronide (ABX464-NGlc). The study was registered at https://www.clinicaltrials (trial number NCT02792686).

Results: ABX464 was well tolerated; the most frequent related treatment-emergent adverse events were head-aches, nausea and vomiting; they were not considered as treatment-limiting effects. ABX464's $C_{\rm max}$ was observed approximately 2 h after administration in all groups. ABX464 was rapidly and substantially metabolized into ABX464-NGIc. The $C_{\rm max}$ of ABX464-NGIc was observed approximately 4 h post-dose and was about 160-fold higher than that of the parent with a much longer $t_{1/2}$ (90–110 h). The ratio of metabolite to parent drug was consistent across the complete dose range.

Conclusions: These studies confirmed that ABX464 is well tolerated and rapidly and substantially metabolized into ABX464-NGIc in human subjects.

Introduction

More than 40 million people have died from HIV-1-related causes globally since the emergence of HIV, and over 30 million people are still infected with the virus.

Since the introduction of combination ART (cART) for HIV infection, millions of AIDS-related deaths have been prevented in the Interrupting therapy results in the virus rapidly rebounding to pretreatment levels.9

Even with the major successes of cART, there are some reports that full life expectancy for HIV-1-infected persons has not been restored. 10,11 Multiple studies have demonstrated that people living with HIV are at increased risk of cardiovascular disease, malignancy and a range of other disorders. 12-15 possibly associated with









Quality Content • Resource Management • Access • Integration • Consultation

Obrigada!!!!

Caso tenha alguma dúvida, por favor não hesite em nos contatar:

EBSCO Brasil Ltda

Ana Carolina Nogueira (21) 2224-0190

anogueira@ebsco.com.br